A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
On a wing and a prayer Leap heads for phase 3.
Opdivo and Yervoy succeed again, but the US path remains unclear.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
The company might need something better to replace its ageing blockbuster.
While Cogent joins the FGFR party.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Just when investors thought things couldn't get any worse, they do.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.